F182112 not checked

Shandong New Time Pharmaceutical Co., LTD · BCMA CD3 · CD38 monoclonal antibody

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
12 active
15 in total · 11 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd)”In the company’s words, NCT07579234 on ClinicalTrials.gov
Tested for
Relapsed or Refractory Multiple Myeloma (RRMM), Relapsed or Refractory Multiple Myeloma, Systemic Lupus Erythematosus (SLE)
Main trialPhase 3
“A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing F182112 with Standard of Care in Patients with Relapsed or Refractory Multiple Myeloma”In the company’s words, NCT07579234 on ClinicalTrials.gov
Other names
Pomalidomide · BCMA CD3 · CD38 monoclonal antibody

Other drugs for Relapsed or Refractory Multiple Myeloma (RRMM)

All 266 drugs for Relapsed or Refractory Multiple Myeloma (RRMM)

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials15

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 25 Jan 2029 A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
Phase 2Recruiting 20 May 2028 A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Phase 1Recruiting 31 Dec 2027 F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus Erythematosus
Phase 1Unknown 30 Jul 2023 Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma
Phase 2Authorised not given Daratumumab, pomalidomide and dexamethasone for del(17p) positive relapsed and relapsed/refractory multiple myeloma patients [DEDALO]
Phase 1/2Authorised not given Pomalidomide as an immune-enhancing agent for the control of HIV (PEACH): An investigator-initiated phase I/IIb clinical trial in people living with HIV on ART and during analytical treatment interruption.
Phase 2Ended not given A phase 2, open label, multicenter, single-stage study to evaluate the efficacy of Isatuximab plus Pomalidomide and Dexamethasone (IPd), in patients with AL amyloidosis not in VGPR or better after any previous therapy
Phase 2Authorised not given Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma induced acute renal failure - "Time is Kidney in the Treatment of myeloma Cast nephropathy" The TIKTAC phase II trial (Pilot-study)
Phase 2Authorised not given A Phase 2 Study of Isatuximab in combination with Pomalidomide and Dexamethasone in MM Patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor
Phase 1/2Authorised not given A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PREVIOUSLY TREATED WITH ONE TO THREE LINES OF THERAPY WHO ARE LENALIDOMIDE REFRACTORY
Phase 2Ended not given ISKPD-IFM2018-03-Multicenter Open label Phase 2 study of Isatuximab plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma
Phase 2Authorised not given A phase II multicenter study of carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy, followed by high-dose therapy with melphalan and autologous peripheral blood stem cell transplantation, consolidation with KRd, and maintenance with lenalidomide and dexamethasone in patients ≤ 70 years old with smoldering multiple myeloma (SMM) with high risk of progression to symptomatic myeloma
Phase 3Authorised not given A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase 1/2Authorised not given Pomalidomide in people with chronic hepatitis B virus (HBV) infection: Safety and immune-enhancing effects (The PIPPI Study)
Phase 2Authorised not given A Phase II, Open-label, Multicenter Study Testing Teclistamab in Combination with Pomalidomide Administered in Alternative Fashion in Participants with RRMM, who Received 1 - 3 Prior Lines of Therapy, Including Lenalidomide and Anti-CD38 Therapy
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow F182112

Following is part of Solo: you see every change to F182112 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in